Skip to main content
S

Sunho Biologics, Inc. — Investor Relations & Filings

Ticker · 2898 HKEX Manufacturing
Open in API
Filings indexed 74 across all filing types
Latest filing 2026-05-04 Regulatory Filings
Country HK Hong Kong
Listing HKEX 2898

About Sunho Biologics, Inc.

http://www.sunho-bio.com.cn

Sunho Biologics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of first-in-class/best-in-class biologics. The company specializes in modulating the immune microenvironment by directly regulating the innate and adaptive immune systems, with a primary therapeutic focus on oncology and autoimmune diseases. Sunho develops various immunotherapies, including antibody-cytokines (immunocytokines). Its core competitive advantage is built upon three proprietary technology platforms: the AIC™ platform for scalable antibody-cytokine fusion protein development; the AEA™ platform, a FUT8 knockout cell line designed to enhance antibody-dependent cell-mediated cytotoxicity (ADCC); and the AIM™ platform, which focuses on developing bispecific/multispecific antibodies based on innate immune stimulation. The company maintains a pipeline of 9 innovative candidates, with 6 currently in clinical development.

Recent filings

Filing Released Lang Actions
Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 30 April 2026
Regulatory Filings
2026-05-04 English
RESUMPTION GUIDANCE
Regulatory Filings
2026-05-03 English
CLARIFICATION ANNOUNCEMENT FURTHER DELAY IN PUBLICATION OF THE 2025 ANNUAL RESULTS AND CONTINUED SUSPENSION OF TRADING
Report Publication Announcement Classification · 1% confidence The document is a regulatory announcement notifying shareholders of a further delay in publishing the Company’s 2025 Annual Results and despatch of its 2025 Annual Report, as well as continued suspension of trading. It does not contain the actual annual results or report itself but rather informs of the timing and publication status of those reports. Therefore, it falls under “Report Publication Announcement” (RPA).
2026-04-27 English
FURTHER SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO THE DELAY IN PUBLICATION OF THE ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2025 AND CONTINUED SUSPENSION OF TRADING
Regulatory Filings
2026-04-21 English
Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 March 2026
Regulatory Filings Classification · 1% confidence The document is a routine monthly return (Form FF301) filed with the Hong Kong Stock Exchange under its Listing Rules, detailing movements in share capital, issued shares, and public float confirmations. It is not a full financial report (10-K or interim/quarterly report), nor is it an investor presentation, dividend notice, M&A, or management change. It also does not announce a specific new share issue or buyback; rather it is a compliance filing under exchange regulations. Therefore, it falls into the general “Regulatory Filings” category (RNS).
2026-04-09 English
SUSPENSION OF TRADING
Regulatory Filings Classification · 1% confidence The document is an official announcement published on the Hong Kong Stock Exchange regarding the suspension of trading in the company’s shares. It does not present financial results, management analysis, or governance rules, nor is it a voting result, delisting notice, or specific report. It is a miscellaneous regulatory announcement filing that does not neatly fit other categories. Therefore it should be classified as a general Regulatory Filing (RNS).
2026-04-01 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.